Page 20 - Path Holdings News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Thyroid Cancer Drugs Market Set for Remarkable Growth: Coverage of Sales of Cabozantinib-s-malate, Caprelsa and Cometriq

/PRNewswire/ The "Thyroid Cancer Drugs Global Market Report 2023" has been added to ResearchAndMarkets.com s offering. With an impressive compound annual.

United statesBristol myersLaura woodAlara pharmaceutical corporationPath holdingsBaxter international incE st office hours callTakeda pharmaceutical companyJerome stevens pharmaceuticals incMylan pharmaceuticals incOffice hours callPfizer incCancer drugs global market reportThyroid cancer drugsWestern europeEastern europe

Bio-Path Holdings, Inc (NASDAQ:BPTH) Sees Large Growth in Short Interest

Bio-Path Holdings, Inc (NASDAQ:BPTH) Sees Large Growth in Short Interest
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesPath holdings incPath company profileRenaissance technologiesVirtu financialCitadel advisorsBio path holdingsGet free reportPath holdingsBio path daily

Bio-Path Holdings, Inc (NASDAQ:BPTH) Sees Significant Growth in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 409,300 shares, a growth of 44.1% from the July 15th total of 284,000 shares. Based on an average trading volume of 298,900 shares, […]

United statesRenaissance technologiesPath holdings incVirtu financialCitadel advisorsBio path holdingsGet free reportPath holdingsBio path dailyBio pathNasdaq bpth

Bio-Path (BPTH) Set to Announce Quarterly Earnings on Tuesday

Bio-Path (NASDAQ:BPTH – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Tuesday, August 15th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Bio-Path (NASDAQ:BPTH – Get Free Report) last issued its quarterly earnings results on Friday, May 12th. The company reported […]

United statesVirtu financialCitadel advisorsPath company profilePath holdings incRenaissance technologiesGet free reportPath holdingsBio path dailyBio pathNasdaq bpth

Bio-Path Holdings, Inc Announces Pricing of $2 1 Million Public Offering

HOUSTON, Aug. 03, 2023 Bio-Path Holdings, Inc., , a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted.

United statesDoug morrisGlobenewswire incExchange commissionProspectus departmentRoth capital partnersStern investor relations incPath holdings incPath holdingsCapital partnersClemente driveAnnual reportInvestor relations